Provigil Cost in Nevada 2026: Modafinil Prices, Insurance, and Every Savings Path

What Does Provigil Actually Cost in Nevada in 2026?

The sticker price for brand-name Provigil in Nevada sits near $850 per month for a standard 30-tablet supply of 200 mg tablets. Generic modafinil tells a very different story. Cash-pay prices at Nevada retail pharmacies average around $80 per month in 2026, a figure roughly 90% below the brand list price. Patients who qualify for a licensed compounded preparation may pay even less, depending on the 503A pharmacy they use and the formulation prescribed.

Brand Provigil vs. Generic Modafinil

Cephalon's brand Provigil and the multiple FDA-approved generic modafinil products contain the same active molecule and the same 200 mg dose strength. The FDA's Orange Book lists modafinil generics as therapeutically equivalent to Provigil, meaning the agency considers them interchangeable for the same indication [1]. For the overwhelming majority of Nevada patients, there is no clinical reason to pay brand pricing when a generic is in stock.

Generic modafinil became widely available after the Cephalon patent disputes settled in the early 2010s [2]. Today, several manufacturers supply the U.S. Market, and competition keeps retail prices near that $80/month median. Prices still vary by pharmacy, so checking two or three Nevada locations or a coupon aggregator before filling is worthwhile.

How Pharmacies Set the Cash Price

Nevada pharmacies are not required to charge a fixed modafinil price. Each chain or independent sets its own cash price, and the same 30-count bottle of generic modafinil 200 mg can range from roughly $40 at a discount warehouse club to $120 at a higher-overhead chain. Third-party coupon platforms negotiate separate pricing agreements that can bring the cost below $60 in many Nevada zip codes.

The U.S. Food and Drug Administration's approved labeling for modafinil outlines the clinical basis for dosing, and no dose adjustment for geography changes what a pharmacist charges [3].

Nevada Medicaid Coverage for Provigil

Nevada Medicaid does not cover Provigil or generic modafinil for narcolepsy, shift-work sleep disorder, obstructive sleep apnea adjunct therapy, or off-label uses such as cognitive enhancement or fatigue in multiple sclerosis. This policy follows a pattern seen in several state Medicaid programs, where wakefulness agents are excluded from the formulary or require prior authorization that is rarely approved.

Why Medicaid Excludes Modafinil

Medicaid formulary decisions are driven by cost-effectiveness data and state budget constraints. Modafinil's cost per quality-adjusted life year compares unfavorably with behavioral interventions for hypersomnia when Medicaid weighs program-wide spending. The Nevada Division of Health Care Financing and Policy updates its preferred drug list periodically, so patients should confirm current status directly with their Medicaid managed care plan, as exceptions can occur for documented treatment failures with covered alternatives.

What Nevada Medicaid Patients Can Do

Patients enrolled in Nevada Medicaid who receive a modafinil prescription have several realistic paths. First, some Medicaid managed care plans (distinct from fee-for-service Medicaid) maintain separate formularies and occasionally cover modafinil with a prior authorization documenting narcolepsy confirmed by polysomnography and multiple sleep latency testing. Second, patient assistance programs from Cephalon's parent company Teva may cover brand Provigil at no cost for patients below an income threshold, typically 400% of the federal poverty level. Third, generic modafinil at $80/month may be affordable outside Medicaid for patients with low copays elsewhere.

The American Academy of Sleep Medicine's 2023 clinical practice guideline on central disorders of hypersomnolence recommends modafinil as a first-line pharmacological treatment for narcolepsy type 1 and type 2, citing a strong evidence base [4]. That recommendation does not obligate Nevada Medicaid to cover it, but it strengthens a prior-authorization appeal.

Does Private Insurance Cover Provigil in Nevada?

Private insurance in Nevada covers modafinil at widely varying rates depending on the plan's formulary tier, the diagnosis code submitted, and whether a prior authorization is in place.

Formulary Tiers and What to Expect

Most Nevada commercial plans place generic modafinil on Tier 2 or Tier 3. A Tier 2 placement typically means a copay between $30 and $60 per month after deductible. Tier 3 placement can push the patient share to $80 to $150 per month. Brand Provigil, when covered at all, usually lands on Tier 4 or Tier 5, which are specialty tiers with coinsurance rather than flat copays; the patient's share can reach $200 to $400 per month even with insurance.

Prior Authorization Requirements

Prior authorization is the single largest barrier to insurance coverage of modafinil in Nevada. Insurers routinely require documentation of one of the three FDA-approved indications, confirmed by a sleep specialist or a board-certified neurologist in many cases. The trial published in Annals of Neurology by the U.S. Modafinil in Narcolepsy Multicenter Study Group (N=271) demonstrated that modafinil 200 mg and 400 mg significantly reduced the Epworth Sleepiness Scale score versus placebo (P<0.001), providing the foundational efficacy data insurers rely on when evaluating PA requests [5].

Submitting a PA with polysomnography results, a multiple sleep latency test showing mean sleep latency below 8 minutes, and a note from a sleep physician gives Nevada patients the strongest chance of approval.

Nevada ACA Marketplace Plans

Plans sold on Nevada's state exchange (Nevada Health Link) are required to cover essential health benefits but are not required to include every drug on the formulary. Modafinil coverage varies by carrier. Anthem, Health Plan of Nevada, and Friday Health Plans (active carriers as of recent plan years) each maintain distinct formularies. A patient comparing plans during open enrollment should filter specifically for modafinil or Provigil in the plan's formulary lookup tool before selecting coverage.

Is Compounded Modafinil Legal in Nevada?

Compounded modafinil is legal in Nevada when prepared by a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. Nevada is not one of the states that has imposed additional restrictions beyond federal 503A requirements, so a licensed Nevada 503A compounding pharmacy may legally prepare modafinil for a patient-specific prescription from a licensed prescriber.

How 503A Compounding Works

Under 503A, a compounding pharmacy may prepare a drug product for an identified individual patient based on a valid prescription. The pharmacist may not compound a copy of a commercially available product without a documented clinical reason, such as a specific dose strength not available commercially, a needed excipient change (for example, removing a dye to which a patient is allergic), or a required alternative delivery route. Generic modafinil tablets are commercially available, so a prescriber ordering compounded modafinil should document the clinical rationale clearly [6].

Cost of Compounded Modafinil in Nevada

Compounded modafinil pricing in Nevada depends on the 503A pharmacy's overhead, the formulation complexity, and the quantity dispensed. Some Nevada patients pay meaningfully less than the $80/month generic cash price through a compounding pharmacy, particularly when the pharmacy sources the active pharmaceutical ingredient at lower cost than finished generics. Patients should request an itemized quote from at least two licensed 503A pharmacies and verify each pharmacy's Nevada Board of Pharmacy license status before filling.

The FDA has not placed modafinil on the list of drugs withdrawn from the market for safety reasons, which is one criterion that must be met for a drug to be compoundable under 503A [7].

The HealthRX clinical team uses the following decision framework for Nevada modafinil patients choosing between generic, brand, and compounded options:

Step 1. Confirm the indication is FDA-approved (narcolepsy, OSA adjunct, shift-work disorder). Off-label use does not preclude prescribing but changes the insurance PA strategy.

Step 2. Check the patient's formulary. If generic modafinil is on Tier 2 or lower, the copay will likely beat cash-pay generic pricing once the deductible is met.

Step 3. If uninsured or the deductible is high, compare GoodRx or similar coupon pricing at three Nevada pharmacies near the patient's zip code.

Step 4. If the patient requires a custom dose, has a documented excipient allergy, or cannot swallow tablets, evaluate a 503A compound with documented clinical rationale in the chart.

Step 5. If Medicaid-enrolled, submit a PA with full sleep-study documentation and an AASM guideline citation. Appeal denials in writing.

Telehealth Prescribing of Provigil in Nevada

Nevada law permits telehealth prescribing of Schedule IV controlled substances, which includes modafinil, when the prescriber holds a valid Nevada license and the telehealth encounter meets the state's standard-of-care requirements. The DEA's special COVID-era telemedicine flexibilities for Schedule III through V substances have been extended through 2025, and legislative proposals in 2024 aimed at making permanent telemedicine prescribing of lower-schedule controlled substances are under ongoing review [8].

What a Nevada Telehealth Visit for Modafinil Requires

A prescriber evaluating a Nevada patient via telehealth for potential modafinil therapy should, at minimum, review prior sleep study results or order new testing if clinically indicated, document symptom history using a validated tool such as the Epworth Sleepiness Scale, rule out untreated obstructive sleep apnea as the primary driver of daytime sleepiness, and confirm the absence of contraindications including hypersensitivity to modafinil or armodafinil, uncontrolled hypertension, or concurrent use of hormonal contraceptives without counseling on reduced efficacy [9].

The FDA label for modafinil notes that hormonal contraceptives may be rendered less effective during modafinil use and for one month after stopping; prescribers must document this counseling [3].

HealthRX Telehealth for Nevada Modafinil Patients

HealthRX providers licensed in Nevada can evaluate patients for sleep disorders and wakefulness indications via synchronous video visit. After a qualifying visit and review of sleep study documentation, a prescription is sent electronically to the patient's preferred Nevada pharmacy. Nevada's electronic prescribing rules for Schedule IV substances are satisfied by a EPCS-compliant e-prescribing platform, which HealthRX uses for all controlled substance orders.

What Is the Cheapest Way to Get Modafinil in Nevada?

For most Nevada patients without insurance coverage, generic modafinil with a third-party coupon from GoodRx, RxSaver, or NeedyMeds applied at a high-volume pharmacy is the most reliably low-cost option. The $80/month average cash price can drop to $40 to $55 at pharmacies that participate in deep-discount generic programs, such as Mark Cuban's Cost Plus Drugs (available for mail-order delivery to Nevada addresses).

Cost Plus Drugs Pricing

Cost Plus Drugs (costplusdrugs.com) listed modafinil 200 mg at a fraction of average retail cash prices as of mid-2025, using a transparent cost-plus-15% markup model. Mail-order delivery to Nevada residential addresses is available. Because modafinil is a Schedule IV substance, the pharmacy must be DEA-registered for mail-order dispensing of controlled substances, which Cost Plus Drugs is. Patients should confirm current pricing and availability directly, as the formulary is updated regularly.

Manufacturer Patient Assistance

Teva Pharmaceuticals, which markets brand Provigil in the United States following its acquisition of Cephalon, operates a patient assistance program. Income eligibility and program terms change, so Nevada patients should apply through the NeedyMeds database or contact Teva directly. Approval typically takes two to four weeks and requires prescriber participation in the application.

Nevada 340B Programs

Federally qualified health centers (FQHCs) and other 340B-covered entities in Nevada can dispense modafinil at 340B pricing to eligible low-income patients. Clark County (Las Vegas) and Washoe County (Reno) each host multiple FQHCs. Patients who receive primary care at an FQHC should ask whether the center's in-house pharmacy or a contract pharmacy participates in 340B for modafinil.

Modafinil Efficacy: The Clinical Evidence Base

Understanding why modafinil commands both a prescription requirement and a meaningful cash price helps Nevada patients make the case for insurance coverage and telehealth visits.

Narcolepsy Trials

The U.S. Modafinil in Narcolepsy Multicenter Study Group randomized 271 patients with narcolepsy to modafinil 200 mg, 400 mg, or placebo. Both active doses reduced Epworth Sleepiness Scale scores significantly compared to placebo (P<0.001), and the 400 mg group showed maintenance of wakefulness test improvements sustained through 9 weeks of treatment [5]. This 1998 trial remains the key registration study cited in the FDA label.

Shift-Work Sleep Disorder

A randomized, double-blind trial published in the New England Journal of Medicine (N=209) tested modafinil 200 mg versus placebo in patients with shift-work sleep disorder. Modafinil reduced sleepiness on the night shift as measured by the Multiple Sleep Latency Test and the Karolinska Sleepiness Scale, with a statistically significant difference from placebo (P<0.001) [10]. The FDA added shift-work sleep disorder as a labeled indication based in part on this evidence.

Obstructive Sleep Apnea Residual Sleepiness

A Cochrane systematic review of modafinil for residual daytime sleepiness in patients with OSA who were adherent to CPAP therapy found a modest but statistically significant reduction in Epworth Sleepiness Scale scores (mean difference approximately 2 points) compared to placebo, with an acceptable adverse event profile [11]. Nevada insurers processing PA requests for OSA-related modafinil prescriptions generally require documented CPAP adherence of at least 4 hours per night on 70% of nights for the preceding 30 days, consistent with the FDA label indication.

Safety Profile Relevant to Nevada Prescribers

Modafinil is generally well tolerated. The most common adverse events in registration trials were headache (occurring in roughly 34% of modafinil-treated patients vs. 23% placebo), nausea (11% vs. 3%), and nervousness (7% vs. 3%) [5]. Serious rash, including Stevens-Johnson syndrome, has been reported rarely; the FDA added a warning to the label in 2007 [3]. Blood pressure monitoring is recommended for patients with a history of hypertension, as modafinil produces small but measurable increases in resting heart rate and blood pressure in some patients [12].

Nevada-Specific Pharmacy and Regulatory Notes

Nevada's Board of Pharmacy regulates all dispensing within the state and maintains a license verification portal where patients can confirm whether a 503A compounding pharmacy is in good standing. The Board has taken enforcement action against out-of-state pharmacies shipping compounded controlled substances into Nevada without proper licensure, so patients ordering from an online compounding pharmacy should verify the pharmacy holds a valid Nevada non-resident pharmacy permit.

The Nevada Revised Statutes chapter on controlled substances (NRS Chapter 453) classifies modafinil as a Schedule IV controlled substance, matching the federal DEA schedule. Prescriptions are valid for 6 months from the date of issue, and refills are permitted up to 5 times within that period, consistent with DEA regulations for Schedule IV drugs [13].

Prescription drug monitoring program (PDMP) participation is mandatory for Nevada prescribers and dispensers of controlled substances. A prescriber writing a modafinil prescription via telehealth must query the Nevada PMP (NV AWIR) before issuing the prescription, and the dispensing pharmacy must report the fill within one business day [14].